2. Ringheim GE, Wampole M, Oberoi K. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures. Front Immunol. 2021 Nov 3;12:662223. doi: ...
10,Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344–58. 11,Ao Zhang , Shi-jun He , Jian-ping Zuo,et al.A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone eros...
4. Woyach J A, Flinn I W, Awan F T, et al. Efficacy and safety of nemtabrutinib, a wild-type and C481S-mutated Bruton tyrosine kinase inhibitor for B-Cell malignancies: Updated analysis of the open-label phase 1/2 ...
13. Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9(21) (来源:阿斯利康网站)
Trial watch: BTK inhibitor shows positive results in B cell malignancies. Nat Rev Drug Discov;11(2):96.Harrison C (2012) Trial watch: BTK inhibitor shows positive results in B cell malignancies. Nature reviews Drug discovery 11:96.Harrison C (2012) Trial watch: BTK inhibitor shows positive ...
[6]Jeff P. Sharman,MD,et al,BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia...
[16]Langrish CL, et al. Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease. J Immunol. 2021 Apr 1;206(7):1454-1468. [17]Ana Giménez-Arn...
1.Smith PF, Redfern A, Shu J, et al. Phase 1 Clinical Trial of PRN2246 (SAR442168), a Covalent BTK Inhibitor Demonstrates Safety,CNS Exposure and Therapeutic Levels of BTK Occupancy[J]. ACTRIMS, Feb 28, 2019, P072. 2.Reich DS, ...
13. Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9(21) (来源:阿斯利康网站) 声明 凡署名原创的文章版权属《肿瘤瞭望》所有,欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用,不代表本平台观点。该等信息不能以任...
1.Smith PF, Redfern A, Shu J, et al. Phase 1 Clinical Trial of PRN2246 (SAR442168), a Covalent BTK Inhibitor Demonstrates Safety,CNS Exposure and Therapeutic Levels of BTK Occupancy[J]. ACTRIMS, Feb 28, 2019, P072. 2.Reich DS, Arnold DL, Vermersch P, et al. Safety and efficacy ...